Incretin Atlas › Trials › TRIUMPH-2 (obesity + T2D)
TRIUMPH-2 (obesity + T2D)
Retatrutide · t2d
Design
- Molecule(s)
- Retatrutide
- Population
- t2d
- Official title
- A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
- Sponsor
- Eli Lilly and Company
- Phase
- 3
- Registry status
- completed · 2023-07 → 2026-06
- Participants
- 1152
- Duration
- 80 weeks
- Registry
- NCT05929079
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| retatrutide 4 mg | t2d | 80 | — | −12.7 % vs −4.0 % Δ −8.7 pp | −11.9 % vs −5.1 % Δ −6.8 pp | −1.4 vs −0.5 | 3.0 vs 5.0 | 10.3 vs 21.5 | 14.0 vs 8.0 | 6.0 vs 4.0 | 8.0 vs 8.0 | −5.0 vs −2.7 | verified |
| retatrutide 9 mg | t2d | 80 | — | −19.1 % vs −4.0 % Δ −15.1 pp | −16.8 % vs −5.1 % Δ −11.7 pp | −1.5 vs −0.5 | 11.0 vs 5.0 | 19.4 vs 21.5 | 21.0 vs 8.0 | 10.0 vs 4.0 | 9.0 vs 8.0 | −7.4 vs −2.7 | verified |
| retatrutide 12 mg | t2d | 80 | — | −20.8 % vs −4.0 % Δ −16.8 pp | −18.8 % vs −5.1 % Δ −13.7 pp | −1.4 vs −0.5 | 7.0 vs 5.0 | 13.9 vs 21.5 | 28.0 vs 8.0 | 16.0 vs 4.0 | 9.0 vs 8.0 | −9.7 vs −2.7 | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (27)
- retatrutide 4 mg · weight_eff · Results, paragraph 4 (efficacy estimand)
–12·7% (SE 0·6) in the 4 mg group
- retatrutide 4 mg · weight_tp · Results, paragraph 4; Table 2
was −11·9% (SE 0·6; −12·9 kg [0·6]) with retatrutide 4 mg
- retatrutide 4 mg · ae_dc · Results, paragraph 2; Figure 1
Ten (3%) participants in the retatrutide 4 mg group
- retatrutide 4 mg · disc_any · Figure 1
30 discontinued study drug
- retatrutide 4 mg · nausea · Results, safety paragraph; Table 3
nausea in 40 [14%], 59 [21%], and 80 [28%] vs 23 [8%]
- retatrutide 4 mg · vomiting · Results, safety paragraph; Table 3
in 16 [6%], 29 [10%], and 45 [16%] vs 12 [4%]
- retatrutide 4 mg · sae · Results, safety paragraph; Table 3
Serious adverse events were reported by 24 (8%) in the retatrutide 4 mg group
- retatrutide 4 mg · hba1c · Results, paragraph 6; Table 2
The mean change from baseline to week 80 in HbA1c was −1·38% (SE 0·06) with retatrutide 4 mg
- retatrutide 4 mg · sbp · Results, paragraph 8; Table 2
−5·0 mm Hg [SE 0·7] with 4 mg
- retatrutide 9 mg · weight_eff · Results, paragraph 4 (efficacy estimand)
–19·1% (0·6) in the 9 mg group
- retatrutide 9 mg · weight_tp · Results, paragraph 4; Table 2
−16·8% (0·7; −18·3 kg [0·8]) with retatrutide 9 mg
- retatrutide 9 mg · ae_dc · Results, paragraph 2; Figure 1
31 (11%) in the retatrutide 9 mg group
- retatrutide 9 mg · disc_any · Figure 1
55 discontinued study drug
- retatrutide 9 mg · nausea · Results, safety paragraph; Table 3
nausea in 40 [14%], 59 [21%], and 80 [28%] vs 23 [8%]
- retatrutide 9 mg · vomiting · Results, safety paragraph; Table 3
in 16 [6%], 29 [10%], and 45 [16%] vs 12 [4%]
- retatrutide 9 mg · sae · Results, safety paragraph; Table 3
25 (9%) in the retatrutide 9 mg group
- retatrutide 9 mg · hba1c · Results, paragraph 6; Table 2
−1·50% (0·07) with retatrutide 9 mg
- retatrutide 9 mg · sbp · Results, paragraph 8; Table 2
–7·4 mm Hg [0·8] with 9 mg
- retatrutide 12 mg · weight_eff · Results, paragraph 4 (efficacy estimand)
and –20·8% (0·6) in the 12 mg group
- retatrutide 12 mg · weight_tp · Results, paragraph 4; Table 2
−18·8% (0·7; −20·7 kg [0·8]) with retatrutide 12 mg
- retatrutide 12 mg · ae_dc · Results, paragraph 2; Figure 1
21 (7%) in the retatrutide 12 mg group
- retatrutide 12 mg · disc_any · Figure 1
40 discontinued study drug
- retatrutide 12 mg · nausea · Results, safety paragraph; Table 3
nausea in 40 [14%], 59 [21%], and 80 [28%] vs 23 [8%]
- retatrutide 12 mg · vomiting · Results, safety paragraph; Table 3
in 16 [6%], 29 [10%], and 45 [16%] vs 12 [4%]
- retatrutide 12 mg · sae · Results, safety paragraph; Table 3
27 (9%) in the retatrutide 12 mg group
- retatrutide 12 mg · hba1c · Results, paragraph 6; Table 2
−1·45% (0·07) with retatrutide 12 mg
- retatrutide 12 mg · sbp · Results, paragraph 8; Table 2
−9·7 mm Hg [0·8] with 12 mg
Primary sources
- Bellido V, le Roux CW, Ekinci EI, Bjornstad P, Frias JP, Giblin K, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026;408(10563):1455-1472. PMID: 42810372.
- ClinicalTrials.gov NCT05929079
How to cite this page
Medical Adviser's Group. Incretin Atlas: TRIUMPH-2 (obesity + T2D). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/triumph-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.